tious use of meta-analysis' find insubstantial evidence of the benefit of IVIG in either prevention or treatment of neonatal sepsis. Using similar data, Weisman et al 2 found the relative risk of infection if IVIG prophylaxis was not given to neonates to be 2-6 (3 2) (mean (SD)), and a relative risk of death in infected neonates not treated with IVIG to be 3 0 (0-7). The authors explain this difference by suggesting use of 'inappropriate statistical methods' by Weisman et al.
Lacy and Ohlsson have heavily pruned published data in search of 'good quality' and 'homogeneity'. In the field of IVIG nothing thus far has been homogenous. All the published data -good or poor quality -have not only differed in entry and outcome criteria but also in basic definitions of variables such as the definition of sepsis and mortality from sepsis. Nor have the authors differentiated between mortality from sepsis and that from unrelated causes or weight groups. Babies that weigh 800 g have a higher mortality from causes other than sepsis than those weighing 2500 g. The authors have also failed to discriminate between studies in which a placebo was used for the control group and studies in which there was no intervention in the control group.
Another bias in this analysis was the uncrit- To avoid bias, we used explicit criteria for the inclusion of studies and definitions of outcomes. Regarding Dr Haque's criticism of our use of mortality from all causes other than death from sepsis, we believe that the outcome of death from all causes is less subject to bias than disease specific mortality. Feinsten has recently written that: 'An important scientific advance can occur in meta-analysis ... if the outcomes become confined to total deaths, rather than the inconsistencies and occasional fantasies cited as disease-specific causes of death'.2
Our use of the random effects model for pooling of data gave less weight to studies with large sample size than if we had used the fixed effects model.
In our discussion we emphasised that the lack of benefit for the prophylactic use of IVIG is based on preparations used to date and that 'new preparations of IVIG with other antibodies or other combinations of antibodies might be effective'. Figure 2 IVIG prophylaxis: effect on sepsis.
Neonatal meningitis with human parvovirus B19 infection EDITOR,-We were interested to read two recent papers by Okumura and Watanabe, on the infection of the central nervous system by human parvovirus B 19 (B1 9) infection.' 2 In these cases, the disease manifest at around school age and not during the neonatal period. Three years ago, we encountered a newborn infant who presented with meningitis and persistent anaemia, presumably related to B 19 infection.
Case report A 20 day old girl was admitted with high fever (398°C). She had been born by normal vaginal delivery, and showed uneventful growth until poor feeding developed on the 17th day of life. On the day of admission, the infant's mother had had low grade fever, joint pains, a rash on all four limbs and headache. Both the infant and the mother had had close contact with the infant's 5 year old brother, who had had erythema infectiosum 17 days previously. Her peripheral leucocyte count was 10-2X109A/, erythrocyte count 3-91X10'2/l, and haemoglobin 127 g/l. A cerebrospinal fluid (CSF) sample indicated severe pleocytosis (861 X 103 leucocytes/ml, with 57% lymphocytes and 43% neutrophils), along with 23x 103 red cells/ml, protein 0 54 g/l, and glucose 2-7 mmol/l. Serum anti-B19 IgG and IgM tested by enzyme linked immunosorbent assays (SRL commercial assay) were positive in both the infant and the mother. Routine cultures of CSF, blood, and throat swabs yielded no pathogenic growth. Aseptic meningitis were diagnosed, and antibiotics (imipenem, cefotaxime, and amikacin) and gamma globulin were started. Her fever
